Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment.
about
Rare Variants Association Analysis in Large-Scale Sequencing Studies at the Single Locus LevelTreatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.Looking back: editors' pick of 2008.Synthesis of PDE IV inhibitors. First asymmetric synthesis of two of GlaxoSmithKline's highly potent Rolipram analogues.
P2860
Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Phosphodiesterase 4 inhibitors ...... ew approach to oral treatment.
@ast
Phosphodiesterase 4 inhibitors ...... ew approach to oral treatment.
@en
type
label
Phosphodiesterase 4 inhibitors ...... ew approach to oral treatment.
@ast
Phosphodiesterase 4 inhibitors ...... ew approach to oral treatment.
@en
prefLabel
Phosphodiesterase 4 inhibitors ...... ew approach to oral treatment.
@ast
Phosphodiesterase 4 inhibitors ...... ew approach to oral treatment.
@en
P2093
P2860
P1476
Phosphodiesterase 4 inhibitors ...... ew approach to oral treatment.
@en
P2093
Chris Skinner
Claire A Butler
Graeme P Currie
Wendy J Anderson
P2860
P304
P356
10.1111/J.1365-2125.2008.03155.X
P407
P577
2008-03-13T00:00:00Z